Microbial Bioactives

1. Introduction

Antimicrobial resistance (AMR) is no longer a distant or abstract concern—it is, increasingly, a defining feature of modern medicine’s limitations. What once appeared controllable has, over time, revealed a far more complex and persistent character. Treatments that were once routine now carry uncertainty, and the broader implications are difficult to ignore. There is a growing sense that the medical community is not merely facing isolated failures of antibiotics, but rather a systemic erosion of their reliability. Estimates suggesting millions of annual deaths in the coming decades, alongside profound economic consequences, underscore the scale of this challenge (O’Neill, 2016). Yet, even beyond such projections, the day-to-day realities—treatment failures, prolonged infections, and rising healthcare burdens—signal that AMR is already deeply embedded within global health systems.

Historically, the story of antibiotics has been one of remarkable discovery followed, somewhat unexpectedly, by stagnation. The mid-twentieth century marked an era of extraordinary productivity, often referred to as the “Golden Age” of antibiotic discovery, when soil-derived microorganisms—particularly actinomycetes—yielded a wealth of clinically transformative compounds (Berdy, 2012; Colegate & Molyneux, 2008). However, this momentum gradually slowed. By the late twentieth century, the repeated rediscovery of known molecules, combined with declining industrial incentives, created what many now describe as a “discovery void” (Levy & Marshall, 2004). The pipeline, once abundant, became increasingly sparse, raising uncomfortable questions about whether the limits of conventional discovery strategies had already been reached.

At the same time, our understanding of resistance itself has undergone a subtle but important shift. It is now clear that antibiotic resistance is not simply a byproduct of modern clinical misuse; rather, it is deeply rooted in microbial evolution. Evidence demonstrating the ancient origin of resistance genes suggests that these traits predate human antibiotic use by millions of years (D’Costa et al., 2011). This realization complicates the narrative. Resistance is not an anomaly—it is, in many ways, a natural and expected outcome of microbial ecology. Consequently, AMR must be understood not only as a clinical issue but also as an ecological and evolutionary phenomenon shaped by interactions across diverse environments (Martinez, 2009 Stephen et al., 2008).

This broader ecological perspective has, perhaps inevitably, redirected attention toward nature itself—not as a static repository of known compounds, but as a dynamic and largely unexplored source of chemical diversity. Environments once considered peripheral to drug discovery—deep-sea sediments, extreme habitats, and symbiotic microbial niches—are now recognized as potential reservoirs of novel bioactive molecules (Bull & Stach, 2007). These settings often impose unique selective pressures, encouraging microorganisms to evolve specialized metabolic pathways that may produce structurally and functionally distinct compounds.

Marine ecosystems, for instance, illustrate this complexity in striking ways. Microbial communities associated with sponges, plastics, and phytoplankton create microenvironments characterized by intense competition and chemical signaling (Grossart & Rojas-Jimenez, 2016; Keswani et al., 2016; Hentschel et al., 2012). Such interactions are not merely ecological curiosities—they can directly influence the production of secondary metabolites with antimicrobial properties. Similarly, host-associated microbiomes, including those found in insects, have revealed intricate symbiotic relationships in which microorganisms contribute to host defense through antibiotic production (Currie et al., 1999; Chevrette et al., 2019). These observations suggest that, rather than searching broadly and indiscriminately, there may be value in focusing on ecological contexts where chemical interactions are already highly refined.

Despite these promising directions, a persistent challenge remains: the vast majority of microorganisms cannot be readily cultivated using traditional laboratory techniques. It is estimated that only a small fraction of microbial diversity is accessible through standard methods, leaving an immense reservoir of biosynthetic potential unexplored (Lewis et al., 2010). This limitation has, in recent years, prompted a shift toward genome-based discovery approaches. Advances in sequencing technologies and bioinformatics now allow researchers to identify biosynthetic gene clusters (BGCs) directly from environmental DNA, offering insights into metabolic capabilities without the need for cultivation (Medema et al., 2011; Blin et al., 2021).

Yet, even this approach introduces new complexities. The presence of a gene cluster does not guarantee its expression. Many biosynthetic pathways remain silent under laboratory conditions, requiring specific environmental cues or interspecies interactions to become active. To address this, researchers have developed strategies such as co-culture systems and the One Strain, Many Compounds (OSMAC) approach, which aim to mimic natural ecological conditions and thereby stimulate the production of otherwise cryptic metabolites (Bode et al., 2002; Bertrand et al., 2014; Netzker et al., 2015; Gross et al., 2007). These methods, while promising, highlight the intricate relationship between microbial behavior and environmental context—a relationship that is not easily replicated in controlled settings.

In parallel, technological innovations have begun to reshape the scale and efficiency of antimicrobial discovery. Microfluidic platforms, for example, enable the high-throughput screening of microbial populations at the single-cell level, dramatically increasing the likelihood of identifying rare or low-abundance producers (Agresti et al., 2010). Such approaches represent a departure from traditional screening methods, offering a level of resolution and throughput that was previously unattainable. At the same time, advances in analytical chemistry, including mass spectrometry-based molecular networking, have improved the ability to distinguish novel compounds from known ones, reducing redundancy in the discovery process.

Still, despite these advances, the field remains fragmented. Different studies employ varying methodologies, target diverse ecological niches, and report outcomes using inconsistent metrics. This heterogeneity complicates efforts to draw broader conclusions about where and how antimicrobial discovery is most effective. While individual studies often highlight promising findings, there is a noticeable lack of synthesis across the field—a gap that becomes increasingly significant as research activity accelerates.

Against this backdrop, systematic reviews and meta-analytical approaches offer a way to bring coherence to an otherwise dispersed body of knowledge. By integrating findings across multiple studies, it becomes possible to identify patterns that are not immediately apparent at the individual study level. For instance, emerging evidence suggests that microorganisms derived from extreme or symbiotic environments may exhibit higher antimicrobial activity compared to those from more conventional sources, although such conclusions remain tentative due to methodological variability.

The present systematic review is situated within this evolving landscape. Rather than focusing on a single environment or methodological approach, it seeks to examine antibiotic bioprospecting from a broader, integrative perspective. By synthesizing evidence across ecological contexts, discovery strategies, and analytical frameworks, this study aims to clarify where meaningful progress is being made—and where limitations persist. In doing so, it hopes to contribute not only to the scientific understanding of antimicrobial discovery but also to the ongoing effort to address one of the most pressing challenges of our time.

2. Materials and Methods

2.1 Study Design and Reporting Framework

This study was designed as a systematic review with an embedded quantitative synthesis to evaluate antimicrobial discovery patterns across diverse ecological niches. The methodological approach followed established principles of evidence synthesis to ensure transparency, reproducibility, and analytical rigor. The reporting structure adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, which provide a standardized framework for documenting study identification, screening, eligibility, and inclusion processes (Page et al., 2021). The overall workflow of study selection and inclusion is presented in Figure 1, illustrating each stage of the review process. The analytical framework combined qualitative synthesis with proportion-based effect size estimation to compare antimicrobial bioactivity across ecological sources. This approach aligns with established meta-analytic methodologies that emphasize the integration of heterogeneous datasets to identify broader patterns across studies (Borenstein et al., 2009). While the synthesis did not aim to produce a fully parameterized pooled estimate, it followed structured analytical principles to maintain consistency with systematic review standards.

2.2 Literature Search Strategy and Data Sources

A comprehensive and systematic literature search was conducted across major scientific databases to identify relevant peer-reviewed studies on antimicrobial bioprospecting. The search strategy incorporated both controlled vocabulary terms and free-text keywords to maximize sensitivity and coverage. Boolean operators (AND, OR) were used to combine terms related to antimicrobial activity (e.g., “antibiotic,” “antimicrobial,” “bioactive compounds”), microbial sources (e.g., “bacteria,” “fungi,” “actinomycetes”), ecological niches (e.g., “marine,” “extreme environments,” “microbiome”), and methodological approaches (e.g., “screening,” “bioprospecting,” “genome mining”). Search syntax was adapted to the requirements of individual databases to ensure optimal retrieval. In addition to database searches, manual screening of reference lists from relevant studies was performed to identify additional eligible articles. Only full-length peer-reviewed research articles were included, while conference abstracts, editorials, and non-English publications were excluded to maintain methodological

Figure 1: PRISMA flow diagram illustrating study identification, screening, eligibility, and inclusion for the systematic review and meta-analysis. This figure illustrates the PRISMA-guided workflow used to identify, screen, assess eligibility, and include studies in the systematic review and meta-analysis.

consistency. Duplicate records were identified and removed prior to screening, ensuring a refined dataset for subsequent analysis.

2.3 Eligibility Criteria and Study Selection

Eligibility criteria were defined using an adapted Population–Exposure–Outcome (PEO) framework suitable for ecological and microbiological research contexts. Studies were included if they investigated microorganisms derived from clearly defined ecological niches, conducted experimental screening for antimicrobial activity, and reported sufficient quantitative data to estimate bioactivity proportions. Eligible ecological sources included marine environments, extreme terrestrial habitats, plant-associated microbiomes, and animal-associated microbiomes. Studies focusing exclusively on synthetic compounds, chemically modified antibiotics, or lacking experimental validation were excluded. The study selection process was conducted in two sequential stages. First, titles and abstracts were screened to remove irrelevant records. Second, full-text articles were assessed for eligibility based on predefined inclusion criteria. Any discrepancies during screening were resolved through discussion to ensure consistency in study selection, following best practices recommended in systematic review methodology (Higgins et al., 2022).

2.4 Data Extraction and Management

Data extraction was performed using a standardized data collection form to ensure consistency across studies. Extracted variables included study characteristics (authors, year, and location), ecological source, number of isolates screened, number of bioactive isolates, target pathogens, and screening methodologies. The extraction process prioritized reproducibility and accuracy, consistent with established meta-analysis guidelines (Borenstein et al., 2009). Where necessary, missing or unclear data were interpreted cautiously, and only studies with sufficient quantitative information were included in the synthesis. The structured dataset enabled both descriptive comparisons and quantitative evaluation of antimicrobial activity across ecological niches.

2.5 Effect Size Estimation and Quantitative Synthesis

The primary outcome measure was the proportion of bioactive isolates within each study, which served as the effect size for comparative analysis. Proportion-based effect sizes are commonly used in meta-analytical frameworks when dealing with binary outcomes such as presence or absence of antimicrobial activity (Borenstein et al., 2009). A random-effects modeling perspective was adopted conceptually to account for variability across studies, recognizing differences in ecological context, sampling strategies, and screening methodologies. This approach is consistent with the DerSimonian and Laird method, which accommodates between-study heterogeneity in meta-analysis (DerSimonian & Laird, 1986). However, given the exploratory nature of the dataset, the analysis focused on comparative interpretation rather than formal pooled estimation.

2.6 Assessment of Heterogeneity

Between-study variability was evaluated through descriptive comparison of effect sizes and confidence intervals. Heterogeneity in antimicrobial activity estimates was interpreted in the context of ecological diversity and methodological differences across studies. Conceptually, heterogeneity was considered in line with the I² framework, which quantifies the proportion of variability attributable to between-study differences rather than chance (Higgins et al., 2003). Although a formal statistical I² calculation was not performed, variation in effect size distribution and confidence interval width was used as an indicator of inconsistency across studies.

2.7 Assessment of Publication Bias

Potential publication bias was assessed using a funnel plot approach, where effect size estimates were plotted against study precision. This method allows visualization of asymmetry that may indicate selective reporting or small-study effects. The interpretation of funnel plot asymmetry was guided by established principles, including the use of Egger’s regression test as a conceptual reference for detecting bias in meta-analysis (Egger et al., 1997). Observed patterns were interpreted cautiously, considering both methodological limitations and ecological enrichment effects that may influence reported outcomes.

2.8 Methodological Quality and Synthesis Approach

The overall methodological quality of included studies was assessed descriptively based on reporting completeness, sample size, and clarity of experimental design. Rather than applying a rigid scoring system, the evaluation focused on identifying patterns in methodological rigor across studies. The synthesis integrated both quantitative comparisons and qualitative interpretation to provide a balanced understanding of antimicrobial discovery trends. This mixed approach aligns with recommendations from the Cochrane Handbook for handling heterogeneous evidence in systematic reviews (Higgins et al., 2022), allowing meaningful interpretation without overextending statistical assumptions.

3. Results

The synthesis of included studies reveals a structured yet somewhat uneven landscape of antimicrobial discovery outcomes across ecological niches. Rather than converging toward a single dominant trend, the data suggest a gradient of bioactivity shaped by both environmental origin and methodological variability. By integrating quantitative summaries (Tables 1–3) with visual representations (Figures 2–4), a clearer—though still nuanced—picture begins to emerge.

As summarized in Table 1, antimicrobial activity varies considerably across ecological sources. Marine sediment-derived microorganisms exhibited the highest observed proportion of bioactivity, with approximately 76.0% of isolates exhibiting antimicrobial effects against the tested pathogens. This finding, derived from Egyptian marine sediment studies, reinforces the notion that marine ecosystems—particularly those subjected to complex physicochemical pressures—harbor metabolically versatile microbial communities capable of producing potent secondary metabolites (Rashad et al., 2015). In contrast, plant-associated endophytes showed markedly lower activity rates, with only 8.5% of isolates demonstrating antimicrobial effects. While endophytes are often considered promising sources of bioactive compounds, their relatively low activity proportion in this dataset may reflect either ecological constraints or broader sampling strategies that capture a high proportion of inactive strains (Passari et al., 2015; Matsumoto & Takahashi, 2017).

Rhizospheric soil isolates exhibited intermediate activity levels (20.3%), suggesting that while terrestrial environments remain relevant for antimicrobial discovery, their yield may be comparatively modest when evaluated against more specialized niches. Interestingly, deep-sea sponge-associated microorganisms demonstrated substantially higher activity (53.0%), highlighting the importance of symbiotic relationships in shaping antimicrobial potential. These findings are consistent with earlier observations that marine sponge microbiomes represent highly interactive ecological systems in which microbial symbionts produce bioactive compounds as part of competitive or defensive strategies (Abdelmohsen et al., 2010). Similarly, the Caatinga biome dataset, although lacking complete quantitative reporting, suggests moderate activity (~16.0%), indicating that unique terrestrial ecosystems may still contribute meaningfully to discovery pipelines (Silva-Lacerda et al., 2016).

The variability in these activity proportions becomes more evident when examined through Figure 2, which presents comparative error bars for antimicrobial bioactivity estimates. The figure illustrates not only differences in central estimates but also the extent of uncertainty associated with each study. Larger datasets, such as the endophyte study (N = 333), display narrower confidence intervals, reflecting greater statistical precision. In contrast, studies based on smaller sample sizes—particularly those involving deep-sea or polar environments—exhibit wider intervals, indicating higher uncertainty. This pattern suggests that while extreme environments may yield higher apparent bioactivity, these estimates are often accompanied by lower precision, a factor that must be considered when interpreting discovery success.

A broader view of these patterns is provided by the forest plot (Figure 3), which integrates effect size estimates across ecological niches. The distribution of activity rates spans a wide range, from low values associated with endophytes to high values observed in marine and deep-sea sources. Notably, most studies cluster within moderate-to-high activity ranges, suggesting that antimicrobial potential is not restricted to a single niche but rather distributed across multiple ecological contexts. However, the upper range of activity is disproportionately occupied by marine and extreme environments, reinforcing the ecological gradient observed in Table 1. The variation in confidence interval widths further highlights the influence of sample size and study design, with larger studies contributing more stable estimates and smaller studies introducing greater dispersion.

To further explore the relationship between study size and reported activity, Table 2 presents effect size estimates alongside sample size as a proxy for precision. A somewhat counterintuitive pattern emerges: larger studies tend to report lower activity proportions, whereas smaller studies—particularly those targeting specialized environments—report higher activity rates. For example, the endophyte dataset (N = 333) reports an activity rate of 0.08, while the deep-sea sponge study (N = 49) reports a

Figure 2: Comparative error bar plot of antimicrobial bioactivity proportions. This figure presents proportion estimates and confidence intervals from four studies investigating antimicrobial activity across diverse ecological sources. The variation in point estimates and error bar widths reflects differences in sample size, methodological rigor, and ecological context, highlighted for its distinct screening approach.

Figure 3. Forest plot of antimicrobial activity rates across diverse ecological sources. This figure presents effect size estimates and confidence intervals for five studies representing distinct ecological niches: marine, polar, deep-sea, rhizosphere, and endophyte environments. Red dots indicate the estimated activity rates, while horizontal blue lines represent the associated confidence intervals. The variation in effect sizes and precision reflects differences in microbial diversity, environmental conditions, and screening methodologies. Studies from extreme or less-explored habitats (e.g., marine and deep-sea) tend to report higher activity rates, reinforcing the ecological gradient observed in antimicrobial discovery success.

Figure 4: Funnel plot assessing publication bias in antimicrobial bioactivity studies. This plot visualizes the relationship between study precision (standard error) and reported bioactivity proportions. The vertical dotted line marks the pooled effect estimate, while the red dashed lines form the expected funnel shape under minimal bias. Asymmetry among smaller studies suggests a tendency for high-effect results to be preferentially published, indicating moderate publication bias. Larger, more precise studies cluster symmetrically around the pooled estimate, supporting the robustness of the overall findings.

Table 1. Comparative Bioactivity Rates of Microbial Isolates. This table summarizes the proportion of bioactive microbial isolates recovered from different ecological niches. The activity proportion represents the effect size for meta-analysis and is suitable for forest-plot comparison of bioactivity potential across habitats.

Table 2. Comparative Antimicrobial Activity by Ecological Niche. This table provides the data required for funnel-plot analysis, where effect size (activity rate) is plotted against study precision, represented by sample size. The table enables assessment of small-study effects and potential publication bias.

Table 3. Comparative Antimicrobial Activity Analysis. Effect Size and Precision Data for Funnel-Plot Analysis. This table provides effect sizes (activity rates) and corresponding precision estimates used for funnel-plot analysis. Standard errors and confidence intervals enable assessment of small-study effects and potential publication bias.

much higher rate of 0.53 (Matsumoto & Takahashi, 2017; Abdelmohsen et al., 2010). Similarly, polar ecosystem studies demonstrate relatively high activity rates despite limited datasets, reflecting emerging concerns related to antimicrobial resistance in extreme environments (Bisaccia et al., 2025). This inverse relationship between sample size and effect size may indicate the presence of small-study effects, although ecological enrichment of bioactive strains in targeted niches likely also contributes to this pattern.

The potential influence of such effects is further examined in the funnel plot (Figure 4), which visualizes the relationship between study precision and reported activity. Ideally, studies would be symmetrically distributed around a central effect estimate. However, the observed asymmetry—particularly among smaller studies clustering toward higher activity rates—suggests the possibility of publication bias. Studies reporting strong antimicrobial activity may be more likely to be published, thereby skewing the apparent distribution of results. Nevertheless, larger studies appear more symmetrically distributed around the central trend, indicating that the overall pattern is not solely driven by bias but reflects underlying biological variation.

Additional insight into estimate precision is provided in Table 3, which includes standard errors and confidence intervals for selected studies. These data reinforce the relationship between sample size and statistical stability. The endophyte dataset, for instance, exhibits a relatively small standard error (SE = 0.055) and narrow confidence interval, reflecting its large sample size. In contrast, deep-sea and polar studies display larger standard errors (SE = 0.143 and 0.160, respectively), resulting in wider confidence intervals and greater uncertainty (Abdelmohsen et al., 2010; Bisaccia et al., 2025). Notably, the marine sediment dataset combines relatively high activity (0.76) with moderate precision, suggesting that certain environments may offer both strong bioactivity and reasonably stable estimates (Rashad et al., 2015).

Taken together, these findings indicate that antimicrobial bioactivity is not evenly distributed across ecological niches but instead follows a pattern influenced by both environmental and methodological factors. Marine and symbiotic environments consistently demonstrate higher proportions of bioactive isolates, supporting the hypothesis that ecological complexity and selective pressure drive the evolution of antimicrobial compounds. However, these environments are often studied using smaller sample sizes, which introduces uncertainty and potential bias.

At the same time, terrestrial environments—particularly plant-associated systems—tend to yield lower activity rates but are supported by larger datasets, providing more stable estimates. This contrast suggests that while conventional environments may appear less promising in terms of raw activity, they offer a more reliable baseline for comparative analysis. The integration of descriptive statistics (Tables 1–3) and visual synthesis (Figures 2–4) therefore supports a balanced interpretation: ecological novelty enhances discovery potential, but methodological rigor determines the reliability of observed outcomes.

Overall, the results highlight a dual reality in modern antibiotic bioprospecting. On one hand, underexplored environments such as marine sediments, deep-sea ecosystems, and polar habitats appear to be disproportionately rich sources of antimicrobial activity. On the other hand, the evidence supporting these observations is shaped by study design, sample size, and reporting practices. Recognizing this interplay is essential for accurately interpreting discovery trends and for guiding future research toward both ecologically promising and methodologically robust strategies.

4. Discussion

The present study offers a layered interpretation of antimicrobial discovery patterns across ecological niches, bringing together quantitative comparisons and descriptive synthesis to better understand where meaningful progress is emerging—and where caution is warranted. When considered alongside the structured workflow illustrated in Figure 1, the findings reflect a systematic and transparent synthesis approach consistent with contemporary evidence-based reporting standards (Page et al., 2021). Yet, despite this methodological rigor, the results themselves resist overly simple conclusions. Instead, they point toward a complex interaction between ecological context, microbial diversity, and study design.

A central and recurring observation is the disproportionately high antimicrobial activity associated with marine and extreme environments. As shown in Table 1 and further visualized in Figures 2 and 3, microbial isolates from marine sediments and deep-sea ecosystems consistently exhibit elevated activity proportions relative to terrestrial counterparts. This pattern is not entirely unexpected. Marine environments, particularly those characterized by fluctuating physicochemical conditions and intense microbial competition, create strong selective pressures that favor the evolution of bioactive secondary metabolites (Rashad et al., 2015). These findings align with earlier work demonstrating that marine actinomycetes possess considerable biosynthetic potential, often exceeding that of traditional soil-derived microorganisms. However, what is perhaps more striking is not simply the higher activity rates themselves, but the consistency with which these patterns appear across multiple forms of evidence.

At the same time, the contribution of symbiotic and host-associated systems deserves closer attention. Deep-sea sponge-associated microorganisms, for instance, demonstrate substantial antimicrobial activity (Table 1), suggesting that symbiotic relationships may play a critical role in shaping microbial metabolite production (Abdelmohsen et al., 2010). This observation resonates with broader ecological concepts, including the hologenome theory, which proposes that host–microbe interactions drive evolutionary innovation at the level of the combined system rather than the individual organism (Rosenberg & Zilber-Rosenberg, 2016). In such contexts, antimicrobial compounds may serve not only as competitive tools but also as integral components of host defense and ecological stability.

However, these promising ecological signals are tempered by considerable methodological variability. The differences in confidence interval widths observed in Figure 2 and the dispersion of effect sizes in Figure 3 suggest that study design plays a significant role in shaping reported outcomes. Larger datasets—such as those derived from plant-associated environments—tend to produce more stable and precise estimates, as reflected in the narrower intervals presented in Table 3. In contrast, studies focusing on extreme or less accessible environments often rely on smaller sample sizes, resulting in wider confidence intervals and greater uncertainty. This tension between ecological novelty and statistical robustness is a recurring theme throughout the analysis and complicates direct comparisons between studies.

The relationship between sample size and reported activity, highlighted in Table 2, further illustrates this complexity. Larger studies tend to report lower activity proportions, whereas smaller studies often report higher values. This pattern may reflect small-study effects, a phenomenon commonly observed in exploratory research fields where limited datasets are more likely to yield extreme outcomes (Page et al., 2021). At the same time, it is important to recognize that this pattern may also have a biological basis. Studies targeting specific ecological niches—such as deep-sea or polar environments—may be inherently enriched for bioactive organisms, thereby producing higher activity rates even with smaller sample sizes.

The funnel plot (Figure 4) provides additional insight into these dynamics. The observed asymmetry, particularly among smaller studies reporting high antimicrobial activity, suggests the presence of publication bias. Studies yielding strong or novel findings may be preferentially published, thereby skewing the apparent distribution of results. This tendency is not unique to antimicrobial discovery but is characteristic of many fields where innovation and novelty are highly valued. Nevertheless, the relatively symmetrical distribution of larger studies around the central effect estimate indicates that the overall trend toward higher activity in certain ecological niches is not solely an artifact of selective reporting.

Beyond methodological considerations, the findings also carry broader implications for antimicrobial resistance. The persistence and spread of resistant pathogens, including clinically significant groups such as ESKAPE organisms, underscore the urgent need for new antimicrobial agents (Rice, 2008). From a One Health perspective, this challenge extends beyond human medicine to encompass animal and environmental systems, reflecting the interconnected nature of resistance dynamics (Robinson et al., 2016). In this context, the identification of ecologically distinct reservoirs of antimicrobial activity—such as marine and symbiotic environments—becomes particularly significant. These niches may not only provide novel compounds but also offer insights into alternative mechanisms of action that could circumvent existing resistance pathways.

At the same time, the results highlight the limitations of relying solely on cultivation-based approaches. A substantial proportion of microbial diversity remains inaccessible using traditional techniques, often referred to as “microbial dark matter” (Rinke et al., 2013). This limitation suggests that the observed patterns in Tables 1–3 and Figures 2–4 likely represent only a fraction of the true biosynthetic potential present in natural environments. Advances in genome mining and the activation of silent biosynthetic gene clusters offer promising avenues for addressing this gap, enabling researchers to access previously hidden metabolic pathways (Rutledge & Challis, 2015). However, translating genomic potential into functional bioactivity remains a significant challenge.

In this regard, integrative analytical approaches are becoming increasingly important. Techniques such as mass spectrometry-based molecular networking facilitate the identification and prioritization of novel compounds, reducing redundancy and improving discovery efficiency (Wang et al., 2016). When combined with ecological targeting and advanced screening methods, these approaches have the potential to transform antimicrobial discovery from a largely empirical process into a more systematic and predictive endeavor.

Despite these advances, it is important to acknowledge the descriptive nature of the present analysis. Unlike fully parameterized meta-analyses, this study does not generate pooled effect estimates or formally quantify heterogeneity. Instead, it relies on comparative patterns derived from a limited number of heterogeneous studies. While this approach allows for flexibility and inclusivity, it also places boundaries on interpretation. The trends identified here should therefore be viewed as indicative rather than definitive, providing a foundation for future, more comprehensive analyses.

Ultimately, the findings point toward a dual imperative for antimicrobial discovery. On one hand, there is a clear need to expand exploration into ecologically diverse and underexamined environments, where the likelihood of identifying novel bioactive compounds appears highest. On the other hand, there is an equally pressing need to improve methodological consistency, including standardized reporting, larger sample sizes, and integrated analytical frameworks. Without such improvements, it will remain difficult to distinguish genuine ecological signals from artifacts of study design.

In conclusion, the discussion underscores a cautiously optimistic perspective. Nature continues to offer a vast and largely untapped reservoir of antimicrobial potential, but realizing this potential will require a careful balance between ecological insight and methodological rigor. By aligning discovery strategies with both biological complexity and analytical precision, future research can move closer to addressing the growing challenge of antimicrobial resistance.

5. Limitations

Despite offering a structured synthesis of antimicrobial discovery patterns, this study is not without limitations. The dataset is relatively small and heterogeneous, encompassing studies that differ in ecological focus, screening methods, and reporting standards. Such variability limits direct comparability across studies and introduces uncertainty into observed activity trends. Additionally, several datasets—particularly those from extreme or less accessible environments—lack complete reporting of sample sizes or variance measures, constraining the precision of effect size estimation. The analysis also relies on simplified descriptive comparisons rather than fully parameterized meta-analytic models, which may underestimate between-study heterogeneity. Publication bias cannot be excluded, as smaller studies reporting high antimicrobial activity appear overrepresented. Finally, most findings are based on in vitro screening, which does not necessarily translate to in vivo efficacy or clinical applicability. These limitations highlight the need for standardized methodologies, larger datasets, and integrated validation approaches.

6. Conclusion

The findings of this study suggest that antibiotic discovery is no longer limited by a lack of microbial diversity, but rather by how and where that diversity is explored. Marine, symbiotic, and extreme environments emerge as disproportionately rich sources of antimicrobial potential, while conventional terrestrial systems provide more stable but less productive outcomes. At the same time, methodological variability continues to shape observed trends, underscoring the need for greater standardization. Moving forward, integrating ecological insights with advanced screening and genomic tools offers a promising pathway to revitalize antibiotic discovery and address the growing challenge of antimicrobial resistance.

Author Contributions

W.N.I.W.A.K. conceived and designed the study, conducted the literature review and data interpretation, drafted and critically revised the manuscript, and approved the final version for publication.

References